Open-label Study of ASP2151 in Herpes Simplex Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A multicenter, open-label study is conducted to evaluate the efficacy and safety of ASP2151
in patients with herpes simplex (recurrent labial/facial herpes and recurrent genital herpes
and Kaposi varicelliform).